As several Indian pharma giants race to launch cheaper generics for Semaglutide, the active ingredient in popular weight-loss drugs Ozempic and Wegovy, international brokerage Jefferies said that Sun Pharma, Lupin and Torrent Pharma can emerge as the eventual winners.Novo Nordisk’s patent for GLP-1 (glucagon-like peptide-1) therapy expired last week. Jefferies in its latest report said that after the patent expiry, more than 10 brands have launched their versions online, and over 40 brands are e...
GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy generics
ਸਰੋਤ: Economic Times
AI ਅਨੁਵਾਦਿਤ ਸਾਰ
ਟਿੱਪਣੀਆਂ (0)
ਲੌਗ ਇਨ ਗੱਲਬਾਤ ਵਿੱਚ ਸ਼ਾਮਲ ਹੋਣ ਲਈ।
ਅਜੇ ਕੋਈ ਟਿੱਪਣੀ ਨਹੀਂ। ਪਹਿਲੀ ਟਿੱਪਣੀ ਕਰੋ!
ਸੰਬੰਧਿਤ ਖ਼ਬਰਾਂ
'Sir, yeh memes band nahi hone chahiye': Raghav Chadha joins meme fest on his Parliament speeches
The 37-year-old Rajya Sabha MP from Punjab has been actively raising a range of everyday issues during the ongoing Budge...
Mint
•
•
1 ਮਿੰਟ ਪੜ੍ਹੋ
Housing sales in Jan-Mar dip 7% from December quarter due to West Asia conflict, up 9% annually: Anarock
Sales increased to 1,01,675 units during the current quarter from 93,280 units in the year-ago period
The Hindu
•
•
1 ਮਿੰਟ ਪੜ੍ਹੋ
30 Days of West Asia conflict: India ups LPG output, focuses on PNG as imports concerns persist
While India has “sufficient” stocks of crude oil, natural gas, petrol, diesel and jet fuel, it faces supply risk with re...
Hindu Business Line
•
•
1 ਮਿੰਟ ਪੜ੍ਹੋ
‘Humanitarian catastrophe’: While the world is focused on the war in Iran, something much worse is unfolding in Lebanon
Following the US-Israeli Operation Epic Fury against Iran, Israel's ground invasion of Lebanon has led to significant ci...
Mint
•
•
1 ਮਿੰਟ ਪੜ੍ਹੋ
Jaishankar raises concerns about food, fuel, fertilizer shortages at G-7 meet
External Affairs Minister stresses importance of resilient trade corridors, such as the IMEC, especially amidst uncertai...
The Hindu
•
•
1 ਮਿੰਟ ਪੜ੍ਹੋ
